The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis
Open accessAbstract
Hepatocellular carcinoma (HCC) is a major cause of cancer‐related death worldwide and currently has the fastest rising incidence of all cancers. Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC. However, acquired resistance to sorafenib has been found in HCC patients, which results in poor prognosis. Here, we show that metallothionein (MT)‐1G is a critical regulator and promising therapeutic target of sorafenib resistance in human HCC cells. The expression of MT‐1G messenger RNA and protein is remarkably induced by sorafenib but not other clinically relevant kinase inhibitors (e.g., erlotinib, gefitinib, tivantinib, vemurafenib, selumetinib, imatinib, masitinib, and ponatinib). Activation of the transcription factor nuclear factor erythroid 2‐related factor 2, but not p53 and hypoxia‐inducible factor 1‐alpha, is essential for induction of MT‐1G expression following sorafenib treatment. Importantly, genetic and pharmacological inhibition of MT‐1G enhances the anticancer activity of sorafenib in vitro and in tumor xenograft models. The molecular mechanisms underlying the action of MT‐1G in sorafenib resistance involve the inhibition of ferroptosis, a novel form of regulated cell death. Knockdown of MT‐1G by RNA interference increases glutathione depletion and lipid peroxidation, which contributes to sorafenib‐induced ferroptosis. Conclusion: These findings demonstrate a novel molecular mechanism of sorafenib resistance and suggest that MT‐1G is a new regulator of ferroptosis in HCC cells. (H epatology 2016;64:488‐500)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Majumder, S., Roy, S., Kaffenberger, T. M., Wang, B., Costinean, S., Frankel, W. L., Bratasz, A., Kuppusamy, P., Hai, T., Ghoshal, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2839 · Cited by 49
RetractedFerroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS
Berry, M. N., & Friend, D. S. (1969) · The Journal of Cell Biology · doi:10.1083/jcb.43.3.506 · Cited by 4,424
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
Self-citationEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
Ferroptosis: Death by Lipid Peroxidation
Yang, W. S., & Stockwell, B. R. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.014 · Cited by 3,088
The role of iron and reactive oxygen species in cell death
Dixon, S. J., & Stockwell, B. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1416 · Cited by 2,381
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012
Self-citationMetallothionein: the multipurpose protein
Coyle, P., Philcox, J. C., Carey, L. C., & Rofe, A. M. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8454-2 · Cited by 1,304
Synchronized renal tubular cell death involves ferroptosis
Linkermann, A., Skouta, R., Himmerkus, N., Mulay, S. R., Dewitz, C., De Zen, F., Prokai, A., Zuchtriegel, G., Krombach, F., Welz, P.-S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415518111 · Cited by 1,126
The Role of Metallothionein in Oxidative Stress
Ruttkay-Nedecky, B., Nejdl, L., Gumulec, J., Zitka, O., Masarik, M., Eckschlager, T., Stiborova, M., Adam, V., & Kizek, R. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036044 · Cited by 839
Toward clinical application of the Keap1-Nrf2 pathway
Suzuki, T., Motohashi, H., & Yamamoto, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.005 · Cited by 680
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
T cell lipid peroxidation induces ferroptosis and prevents immunity to infection
Matsushita, M., Freigang, S., Schneider, C., Conrad, M., Bornkamm, G. W., & Kopf, M. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140857 · Cited by 672 · cited 1×
“In addition to cancer therapy,((28)) impaired ferroptosis involves tissue injury,((26,35)) immunity tolerance,((36)) and stem cell division.”
BackgroundHSPB1 as a novel regulator of ferroptotic cancer cell death
Sun, X., Ou, Z., Xie, M., Kang, R., Fan, Y., Niu, X., Wang, H., Cao, L., & Tang, D. (2015) · Oncogene · doi:10.1038/onc.2015.32 · Cited by 666
Self-citationRegulated necrosis: disease relevance and therapeutic opportunities
Conrad, M., Angeli, J. P. F., Vandenabeele, P., & Stockwell, B. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.6 · Cited by 630
Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J., Mazière, J., Chauffert, B., & Galmiche, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28159 · Cited by 602
PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis
Yang, L., Xie, M., Yang, M., Yu, Y., Zhu, S., Hou, W., Kang, R., Lotze, M. T., Billiar, T. R., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms5436 · Cited by 502
Self-citationHayano, M., Yang, W. S., Corn, C. K., Pagano, N. C., & Stockwell, B. R. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.93 · Cited by 457
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Lachaier, E., Louandre, C., Godin, C., Saidak, Z., Baert, M., Diouf, M., Chauffert, B., & Galmiche, A. (2014) · PubMed · Cited by 420
Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming
Gascón, S., Murenu, E., Masserdotti, G., Ortega, F., Russo, G. L., Petrik, D., Deshpande, A., Heinrich, C., Karow, M., Robertson, S. P., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2015.12.003 · Cited by 360
Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M.-L., Schreiber, S., & Schäfer, H. (2013) · Oncogene · doi:10.1038/onc.2012.493 · Cited by 330
Wang, X. J., Hayes, J. D., Henderson, C. J., & Wolf, C. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709483104 · Cited by 309
High-Mobility Group Box 1 Is Essential for Mitochondrial Quality Control
Tang, D., Kang, R., Livesey, K. M., Kroemer, G., Billiar, T. R., Van Houten, B., Zeh, H. J., & Lotze, M. T. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.008 · Cited by 296
Self-citationLiang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. (2013) · Hepatology · doi:10.1002/hep.26224 · Cited by 289
Yan, W., Chang, Y., Liang, X., Cardinal, J. S., Huang, H., Thorne, S. H., Monga, S. P. S., Geller, D. A., Lotze, M. T., & Tsung, A. (2012) · Hepatology · doi:10.1002/hep.25572 · Cited by 241
Isolation and Culture of Primary Hepatocytes from Resected Human Liver Tissue
LeCluyse, E. L., & Alexandre, E. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-688-7_3 · Cited by 167
The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage
Wang, P., Yu, J., & Zhang, L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700020104 · Cited by 163
Eckschlager, T., Adam, V., Hraběta, J., Figova, K., & Kizek, R. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309788922243 · Cited by 144
Datta, J., Majumder, S., Kutay, H., Motiwala, T., Frankel, W. L., Costa, R. H., Cha, H. C., MacDougald, O. A., Jacob, S. T., & Ghoshal, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4433 · Cited by 132
Sorafenib: Where Do We Go from Here?
Siegel, A. B., Olsen, S. K., Magun, A. M., & Brown, R. S. (2010) · Hepatology · doi:10.1002/hep.23633 · Cited by 109
Wei, J., Meng, F., Qu, K., Wang, Z., Wu, Q., Zhang, L.-Q., Pang, Q., & Liu, C. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.122 · Cited by 104
Nomoto (2009) · International Journal of Oncology · doi:10.3892/ijo_00000359 · Cited by 96
Galmiche, A., Chauffert, B., & Barbare, J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.12.028 · Cited by 85
Metallothionein – Immunohistochemical Cancer Biomarker: A Meta-Analysis
Gumulec, J., Raudenská, M., Adam, V., Kizek, R., & Masařík, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085346 · Cited by 70
Increased Expression of Metallothionein Is Associated with Irinotecan Resistance in Gastric Cancer
Chun, J. H., Kim, H. K., Kim, E. S., Kim, I.-H., Kim, J. H., Chang, H. J., Choi, I. J., Lim, H., Kim, I.-J., Kang, H. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1063 · Cited by 53
The role of metallothioneins in anticancer drug resistance
Bahnson, R. R., Basu, A., & Lazo, J. S. (1991) · Cancer treatment and research · doi:10.1007/978-1-4615-3872-1_12 · Cited by 14
Cited by
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
Self-citationGalluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationFerroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
Self-citationFerroptosis: past, present and future
Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., Sun, B., & Wang, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2298-2 · Cited by 4,171
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897
Self-citation
Metadata
- Authors
- Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., & Tang, D.
- Venue
- Hepatology
- Published
- 2016-05-24
- Volume
- 64
- Issue
- 2
- Pages
- 488-500
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2305753128
- Cited by
- 703
- References
- 47
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.